Touchstone Innovations throws another £3m at promising Pulmocide

Josh White Sharecast | 20 Mar, 2017 16:00 - Updated: 16:00 | | |

money pounds cash

Touchstone Innovations

304.63

17:17 21/07/17
0.58%
1.75
  • 10,844.78
  • 0.17%18.29
  • Max: 10,865.77
  • Min: 10,794.09
  • Volume: 0
  • MM 200 : n/a
17:30 21/07/17

Touchstone Innovations announced on Monday that it participated in a £25m Series B funding round in Pulmocide, committing £3m to the round alongside new investors SR One and Longwood Fund, plus existing investors SV Life Sciences, F-Prime Capital, and Johnson & Johnson Innovation.

The AIM-traded company described Pulmocide as a privately-held drug development company located in London, which was developing novel small molecule inhaled medicines for the treatment of life threatening respiratory infections caused by respiratory syncytial virus (RSV) and Aspergillus.

It said the new funding would enable Pulmocide to advance its assets through early clinical development.

Pulmocide was reportedly on track to deliver proof of concept data in RSV using its highly potent inhaled RSV antiviral agent ‘PC786’ in human RSV challenge and in infants hospitalised with bronchiolitis due to RSV infection.

Pulmocide would also be progressing its ‘PC945’, described as a potent azole antifungal for the treatment of pulmonary Aspergillosis, including fungal asthma, pulmonary Aspergilloma, Aspergillus infections in lung transplant recipients and patients with cystic fibrosis.

“We continue to support this strong entrepreneurial management team to progress the company's two novel compounds through early clinical development; another step closer to a treatment for patients with life-threatening lung infections,” said Touchstone’s director of healthcare ventures Maina Bhaman.

“Pulmocide is yet another example of a portfolio company that has been able to attract a powerful group of investors and we would like to welcome SR One and Longwood to the syndicate.”

As at 31 July, Touchstone Innovations had a 24.1% interest in the issued share capital of Pulmocide.

Following the new investment, it will hold an 18.5% stake in the issued share capital of the company.

More news

19:01 Commodities: Increasing supply of oil weighs heavy on the market

An over supply of crude from Nigeria and Libya of approximately 1m barrels per day weighed heavily on the oil market on Friday with September contracts for both WTI crude and Brent crude down 2.28% and 2.29% respectively.

18:58 Magnolia Petroleum announces divestment of North Dakota and Oklahoma wells

Magnolia Petroleum, an Oklahoma based oil and gas investment company, has divested and agreed farmouts over several wells in North Dakota and Oklahoma for a total of $411,000.

18:55 Europe close: DAX dives on euro peaks and colluding carmakers

European stocks ended the week firmly in the red as the euro continued to march higher, with the strength in the single currency weighing on exporters and car makers were hit by reports of collusion in the industry, combining to send the Dax to new three-month lows.

18:34 FX round-up: Lack of data release makes way for indecisive Cable moves

On Friday sterling managed to recover most of its losses against the US dollar from prior session posting a morning high of 1.3020, only managing to touch psychological resistance of 1.3000 briefly.

17:29 London close: FTSE profit taking kicks shares into red

UK stocks were lacklustre on Friday as oil and stocks plunged but investors mulled yet more waxing and waning of Brexit negotiations, proving that uncertainty is the only certainty surrounding the issue.

17:07 FTSE 100 movers: Paddy Power leads Friday retreat

London's FTSE 100 was in the red on Friday, along with stock benchmarks in Europe and the US.

16:36 General Electric tumbles further as profits slide

US industrial giant General Electric reported net profits of $1.34bn for the second quarter of 2017, 53% less than its earnings for the same quarter in 2016.

16:25 US open: Wall Street slips amid weak tech earnings, downbeat GE

Wall Street was slightly lower in early trading following disappointing updates from Microsoft and Ebay, alongside weak guidance from industrial conglomerate GE.

16:03 Catalyst Media softens blow from failed Greyhound track bids

Retail betting service supplier Sports Information Services (SIS), in which Catalyst Media Group holds a 20.5% stake, has secured rights and media agreements for its greyhound and horseracing content.

16:00 Dalata buys Hotel La Tour for £31m

AIM-listed Dalata has acquired Hotel La Tour for £31m from Hotel La Tour Limited, which owns the long leasehold interest in the hotel situated on Park Street in the centre of Birmingham.